Mersana Net Income Applicable To Common Shares from 2010 to 2026
| MRSN Stock | USD 29.08 0.18 0.62% |
Net Loss | First Reported 2015-12-31 | Previous Quarter -56.2 M | Current Value -54.3 M | Quarterly Volatility 20.5 M |
Check Mersana Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Mersana Therapeutics' main balance sheet or income statement drivers, such as Interest Income of 10.2 M, Depreciation And Amortization of 1.1 M or Interest Expense of 4.7 M, as well as many indicators such as Price To Sales Ratio of 3.7, Dividend Yield of 0.0 or Days Sales Outstanding of 389. Mersana financial statements analysis is a perfect complement when working with Mersana Therapeutics Valuation or Volatility modules.
Mersana | Net Income Applicable To Common Shares | Build AI portfolio with Mersana Stock |
Evaluating Mersana Therapeutics's Net Income Applicable To Common Shares across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Mersana Therapeutics's fundamental strength.
Latest Mersana Therapeutics' Net Income Applicable To Common Shares Growth Pattern
Below is the plot of the Net Income Applicable To Common Shares of Mersana Therapeutics over the last few years. It is the net income that remains after preferred dividends have been deducted, available to common shareholders. Mersana Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Mersana Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Net Income Applicable To Common Shares | 10 Years Trend |
|
Net Income Applicable To Common Shares |
| Timeline |
Mersana Net Income Applicable To Common Shares Regression Statistics
| Arithmetic Mean | (86,621,945) | |
| Coefficient Of Variation | (94.28) | |
| Mean Deviation | 73,268,170 | |
| Median | (38,707,000) | |
| Standard Deviation | 81,669,040 | |
| Sample Variance | 6669.8T | |
| Range | 190.5M | |
| R-Value | (0.89) | |
| Mean Square Error | 1517.3T | |
| R-Squared | 0.79 | |
| Slope | (14,345,031) | |
| Total Sum of Squares | 106717.3T |
Mersana Net Income Applicable To Common Shares History
About Mersana Therapeutics Financial Statements
Mersana Therapeutics investors utilize fundamental indicators, such as Net Income Applicable To Common Shares, to predict how Mersana Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Loss | -183.8 M | -174.6 M |
Pair Trading with Mersana Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Mersana Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mersana Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Mersana Stock
Moving against Mersana Stock
| 0.94 | DWTX | Dogwood Therapeutics | PairCorr |
| 0.85 | EDIT | Editas Medicine Earnings Call This Week | PairCorr |
| 0.84 | ABP | Abpro Holdings | PairCorr |
| 0.83 | GNLX | Genelux Common | PairCorr |
| 0.77 | KURA | Kura Oncology | PairCorr |
The ability to find closely correlated positions to Mersana Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Mersana Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Mersana Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Mersana Therapeutics to buy it.
The correlation of Mersana Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Mersana Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Mersana Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Mersana Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in producer price index. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Will Biotechnology sector continue expanding? Could Mersana diversify its offerings? Factors like these will boost the valuation of Mersana Therapeutics. Expected growth trajectory for Mersana significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Mersana Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (13.95) | Revenue Per Share | Quarterly Revenue Growth (0.13) | Return On Assets | Return On Equity |
Investors evaluate Mersana Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Mersana Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Mersana Therapeutics' market price to deviate significantly from intrinsic value.
Understanding that Mersana Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Mersana Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Mersana Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.